[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"19899ca6-56d4-4952-beaa-c4745d820e14","acronym":"","url":"https://clinicaltrials.gov/study/NCT03131908","created_at":"2021-01-18T15:25:52.146Z","updated_at":"2025-02-25T13:12:18.989Z","phase":"Phase 1/2","brief_title":"Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss","source_id_and_acronym":"NCT03131908","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-13"},{"id":"658df07a-1501-4c8c-8a3c-b8a40f1a83dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439149","created_at":"2021-01-18T21:22:06.430Z","updated_at":"2024-07-02T16:35:04.598Z","phase":"Phase 2","brief_title":"Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)","source_id_and_acronym":"NCT04439149","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-09"},{"id":"97b43e3f-fef1-4710-bf54-e72318c22ed1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439188","created_at":"2021-01-18T21:22:07.541Z","updated_at":"2024-07-02T16:35:05.160Z","phase":"Phase 2","brief_title":"Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)","source_id_and_acronym":"NCT04439188","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN loss","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-08"},{"id":"bed0d4a8-8053-4726-881a-8fd3a77fe815","acronym":"","url":"https://clinicaltrials.gov/study/NCT02951091","created_at":"2021-01-18T14:29:37.726Z","updated_at":"2024-07-02T16:36:07.027Z","phase":"Phase 2","brief_title":"Biomarker-Integrated Umbrella, Advanced Gastric Cancer","source_id_and_acronym":"NCT02951091","lead_sponsor":"Yonsei University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • GSK2636771"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-20"},{"id":"276d0a32-62b9-4cd9-b652-5c83c87e2a19","acronym":"","url":"https://clinicaltrials.gov/study/NCT02615730","created_at":"2021-01-18T12:42:23.664Z","updated_at":"2024-07-02T16:36:31.358Z","phase":"Phase 1/2","brief_title":"PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma","source_id_and_acronym":"NCT02615730","lead_sponsor":"Yonsei University","biomarkers":" PTEN • PIK3CB","pipe":"","alterations":" ","tags":["PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • GSK2636771"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2021","study_completion_date":" 03/31/2021","last_update_posted":"2021-04-22"},{"id":"cd2d3973-b09a-47d1-9905-179fbe08c625","acronym":"","url":"https://clinicaltrials.gov/study/NCT02215096","created_at":"2021-01-18T10:23:00.105Z","updated_at":"2024-07-02T16:36:39.797Z","phase":"Phase 1","brief_title":"Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT02215096","lead_sponsor":"GlaxoSmithKline","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • GSK2636771"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 11/13/2014","start_date":" 11/13/2014","primary_txt":" Primary completion: 10/03/2019","primary_completion_date":" 10/03/2019","study_txt":" Completion: 10/03/2019","study_completion_date":" 10/03/2019","last_update_posted":"2020-10-22"},{"id":"cc35a732-a32f-424d-b664-a540e6b1f7ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01458067","created_at":"2021-01-18T06:03:31.538Z","updated_at":"2024-07-02T16:37:08.736Z","phase":"Phase 1/2","brief_title":"A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency","source_id_and_acronym":"NCT01458067","lead_sponsor":"GlaxoSmithKline","biomarkers":" HER-2 • PGR • PTEN","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GSK2636771"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 11/10/2011","start_date":" 11/10/2011","primary_txt":" Primary completion: 11/12/2015","primary_completion_date":" 11/12/2015","study_txt":" Completion: 02/25/2016","study_completion_date":" 02/25/2016","last_update_posted":"2018-07-24"}]